Nothing Special   »   [go: up one dir, main page]

Khan et al., 2023 - Google Patents

An overview of 1, 2, 3-triazole-containing hybrids and their potential anticholinesterase activities

Khan et al., 2023

View HTML
Document ID
14390456986104388789
Author
Khan S
Akhtar M
Gogoi U
Meenakshi D
Das A
Publication year
Publication venue
Pharmaceuticals

External Links

Snippet

Acetylcholine (ACh) neurotransmitter of the cholinergic system in the brain is involved in learning, memory, stress responses, and cognitive functioning. It is hydrolyzed into choline and acetic acid by two key cholinesterase enzymes, viz., acetylcholinesterase (AChE) and …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Similar Documents

Publication Publication Date Title
Khan et al. An overview of 1, 2, 3-triazole-containing hybrids and their potential anticholinesterase activities
Matiadis et al. Pyrazoline hybrids as promising anticancer agents: An up-to-date overview
Cheke et al. Therapeutic outcomes of isatin and its derivatives against multiple diseases: Recent developments in drug discovery
Fan et al. Coumarin–triazole hybrids and their biological activities
Peitzika et al. A review on recent approaches on molecular docking studies of novel compounds targeting acetylcholinesterase in Alzheimer disease
Li et al. Pyrazole scaffold synthesis, functionalization, and applications in Alzheimer’s disease and Parkinson’s disease treatment (2011–2020)
Chowdhary et al. A mini review on isatin, an anticancer scaffold with potential activities against neglected tropical diseases (NTDs)
Cheong et al. Current pharmacotherapy and multi-target approaches for Alzheimer’s disease
Biersack et al. Recent developments concerning the application of the Mannich reaction for drug design
Hiremathad et al. Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy
Jiaranaikulwanitch et al. From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer’s disease
Pereira et al. Recent advances in bioactive flavonoid hybrids linked by 1, 2, 3-triazole ring obtained by click chemistry
Ibrahim et al. Mechanochemical synthesis and molecular docking studies of new azines bearing indole as anticancer agents
Gonnet et al. Synthesis of biologically relevant 1, 2, 3-and 1, 3, 4-triazoles: From classical pathway to green chemistry
Silva et al. Recent synthetic approaches towards small molecule reactivators of p53
Chouchène et al. Antimicrobial activity and DFT studies of a novel set of spiropyrrolidines tethered with thiochroman-4-one/chroman-4-one scaffolds
Mancini et al. Hybrid molecules containing naphthoquinone and quinolinedione scaffolds as antineoplastic agents
Ammar et al. Development and radiosterilization of new Hydrazono‐quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study
Vishnu et al. Experimental and computational evaluation of piperonylic acid derived hydrazones bearing isatin moieties as dual inhibitors of cholinesterases and monoamine oxidases
Bubley et al. Tacrine-based hybrids: past, present, and future
Mustafa et al. Antimicrobial pyridazines: synthesis, characterization, cytotoxicity, substrate promiscuity, and molecular docking
Rodríguez-Arce et al. Oxoisoaporphines and aporphines: Versatile molecules with anticancer effects
Dorababu Pharmacological report of recently designed multifunctional coumarin and coumarin–heterocycle derivatives
Barresi et al. Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Boraei et al. Synthesis of new functionalized indoles based on ethyl indol-2-carboxylate